Medivation Reports Third Quarter Financial Results and Provides Corporate Update


(Marketwired) – 11/06/14 – Medivation, Inc. (NASDAQ:MDVN) today reported its financial results for the third quarter ended September 30, 2014. U.S. net sales of XTANDI® (enzalutamide) capsules for the quarter, as reported by Astellas Pharma Inc., were $181.4 million (+67% vs. prior year). Ex-U.S. net sales of XTANDI for the quarter, as reported by Astellas, were $119.6 million… Read more »

Shares of Medivation closed yesterday at $107.94 . MDVN has a 1-year high of $117.23 and a 1-year low of $54.37. The stock’s 50-day moving average is $104.48 and it’s 200-day moving average is $96.99.

On the ratings front, Medivation has been the subject of a number of recent research reports. In a report released yesterday, Stifel Nicolaus analyst Joel Sendek reiterated a Buy rating on MDVN, with a price target of $128, which reflects a potential upside of 18.6% from last closing price. Separately, on January 22, Brean Murray Carret’s Jonathan Aschoff maintained a Buy rating on the stock and has a price target of $118.

In total, 9 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $107.94 which is 14.0% above where the stock closed yesterday.

Medivation, Inc. is a biopharmaceutical company engaged in the development of novel small molecule drugs to treat diseases like Alzheimer’s disease and Huntington disease.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts